Hungary Seeks Higher Patient Drug Charges

18 November 1996

Hungary's Finance Ministry says it favors an increase in the amount paid by patients for drugs in 1997, so that the Health Insurance Fund's 1997 budget targets are met, reports MTI Econews. The Fund's 1997 draft budget allocates 86 billion forint ($570.3 million) for medicine price subsidies, compared to the amended 1996 budget of 76 billion forint.

The Finance Ministry proposes ending the 100% subsidy on drugs for the treatment of certain kinds of illnesses and making the level of income the only criterion for eligibility for free drugs. The number of Hungarians entitled to free medicines rose from 300,000 in 1995 to 550,000 in 1996, say Ministry figures. In the long term, it says, the Fund should provide only partial funding for certain kinds of health services, and foresees a greater role for private health insurance schemes. People who cannot afford private health insurance should be able to apply for support from local councils, it says.

Meantime, national officials have said that Hungarian drugs producers have nothing to fear from the monitoring of their production practices by the European Union to determine whether these practices meet EU regulations, reports MTI Econews. This proposal has been made by Hungary before it becomes a member of the EU.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight